Variant · Expression
HDAC9 Overexpression
CI-VAR-00003216Explore in graph →CIViC 3306
Curated evidence
Evidence by cancer (2 items)
Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.
- Source
- CIViC — Clinical Interpretation of Variants in Cancer
- Dataset
- CIViC evidence items
- Version
- civic-2026-09-08
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Evidence
- expert curation
- License
- CC0 1.0
- PMID
- 26930713
- Run
- ING-CIVIC-20260908-000001
| Molecular profile | Therapy | Type | Level | Direction · significance | Rating (1–5) | Status | Evidence | Source |
|---|---|---|---|---|---|---|---|---|
| Malignant Breast Neoplasm1 | ||||||||
| HDAC9 Overexpression | Panobinostat + Trichostatin A + VorinostatSubstitutes | Predictive | B | Supports Resistance | 3 | submitted | EID9230As basal breast cancers display one of the most aggressive phenotypes in cell lines and commonly indicate poor prognosis in patients, assessing HDAC9’s variability among different cell types may evinc… (full text at CIViC) PMID 26930713 · Lapierre et al., 2016 · Open in CIViC | civic |
| Malignant Esophageal Neoplasm1 | ||||||||
| HDAC9 Overexpression | HDAC Inhibitor REC-2282 | Predictive | D | Supports Sensitivity Response | 2 | submitted | EID9855In 62 esophageal carcinoma tumor samples, HDAC1 expression was found to considerably increase by 82% compared to adjacent non-tumor tissues with (18.2%) and identified as HDAC1 positive. HDAC1 positiv… | |
ClinVar
Clinical significance (0)
ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.
Data not yet available